Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-438 in Healthy Men
NCT02141711Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonoprazan in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (5 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration at Day 7, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at Day 7 and 3 more. Started Oct 2008; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02141711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141711.